Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16142382 | 0.92 | ESR2 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19085369 | 0.85 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL21802643 | 0.83 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL8489 | 0.83 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17472324 | 0.82 | PKM (0.79) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17881267 | 0.82 | RXFP1 (0.66) | CA1CA2MAPK1ALDH1A1NPC1 | |
| SCHEMBL19335942 | 0.78 | CA1 (0.42) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL11373286 | 0.76 | CA1 (0.85) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11255612 | 0.75 | — | — | |
| SCHEMBL10304839 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018132-A1 | 5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER | GODAVARI BIOREFINERIES LTD. (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240019607-A1 | Optical Multilayer Structure and Method of Manufacturing the Same | SK INNOVATION CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-11061287-B2 | Photo alignment agent and liquid crystal display | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-07-13 | — | — | US | disclosed |
| US-20200110315-A1 | PHOTO ALIGNMENT AGENT AND LIQUID CRYSTAL DISPLAY | SAMSUNG DISPLAY CO LTD (KR) | 2020-04-09 | — | — | US | disclosed |
| US-10539832-B2 | Photo alignment agent and liquid crystal display | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-01-21 | — | — | US | disclosed |
| WO-2018010637-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | SHANGHAI METON PHARMACEUTICAL CO., LTD (CN) | 2018-01-18 | — | — | WO | disclosed |
| EP-1994004-B9 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018132-A1 | 5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER | HSD17B11, HSD17B1, HSD3B1 | CA1 3546/4885CA2 3978/4885CA7 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.